ClinicalTrials.gg
CompletedNCT07538570Updated Nov 12, 2026

Evaluation of Pain Treatment After Total Knee Arthroplasty

A Phase 4 interventional study of Suzetrigine and Placebo in Pain, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 4, Interventional, and Treatment

Updated Nov 12, 2026Now CompletedNow Active, not recruiting+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing suzetrigine in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. suzetrigine · Pain.

Enrollment
9th of 21
66 · median 50
Started
2026
with 5 others
Phase 4
3 of 21
2 open now
Registered
18th of 21
by date
Lead sponsor
15 of 21
Vertex Pharmaceuticals Incorporated

Among the 21 studies testing suzetrigine in Pain, this one is the 9th largest by enrollment, is one of 6 that started in 2026, is one of 3 in phase 4, and was the 18th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 21 studies testing suzetrigine in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About suzetrigine

suzetrigine: first FDA approval 2025 (JOURNAVX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing suzetrigine in Pain, or all of them as a file.
02

Study summary

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

03

Conditions studied

  • Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2)
  • Scheduled to undergo an elective primary unilateral TKA surgery

Key Exclusion Criteria:

- History of previous TKA surgery on incident side

Other protocol defined Inclusion/Exclusion criteria will apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Suzetrigine (SUZ)

    Participants will receive SUZ for 14 days.

    Drug: Suzetrigine

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to SUZ for 14 days

    Drug: Placebo

Interventions

  • Tablets for oral administration.

    Also known as: VX-548, JOURNAVX

  • DrugPlacebo

    Placebo matched to SUZ for oral administration

06

What researchers measure

Primary outcomes

  1. Total Opioid Usage

    Time frame: 24 hours to 168 hours after the first dose of study drug

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2026 to primary completion in Oct 2026, 5 months.

Of 295 phase 4 interventional studies under Pain, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's 5 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2027 → Oct 2026 and completion Jan 2027 → Oct 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 20, 2026
StartActual
Apr 24, 2026
Primary completionActual
Oct 12, 2026was Jan 2027
CompletionActual
Oct 22, 2026was Jan 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Completed
changed Oct 28, 2026 · changed Nov 12, 2026
Primary completion
Jan 30, 2027→Oct 12, 2026 (actual)
Nov 12, 2026
Study completion
Jan 30, 2027→Oct 22, 2026 (actual)
Nov 12, 2026
Enrollment
60 (estimated)→66 (actual)
Oct 28, 2026
Show all 2 updates
  1. Nov 12, 2026
    Active, not recruiting→Completed
    Primary completion Jan 30, 2027→Oct 12, 2026 (now actual)
    Study completion Jan 30, 2027→Oct 22, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 28, 2026
    Recruiting→Active, not recruiting
    Enrollment 60 (estimated)→66 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07538570
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Apr 24, 2026
Primary completion
Oct 12, 2026
Completion
Oct 22, 2026
Last update
Nov 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suzetrigine

Start the discussion